Physician profile
Robert G Spratt
NPI 1578550554
$3,526.49
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,574 · 2020: $936 · 2022: $16.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.62 | 2019-2020 | |
| Amarin Pharma, INC. | $364.19 | 2019-2020 | |
| Pfizer INC. | $299.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $287.22 | 2019-2020 | |
| Amgen INC. | $223.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $216.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $192.08 | 2019-2020 | |
| Allergan, INC. | $154.83 | 2019-2020 | |
| Abbvie INC. | $153.22 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $113.44 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $107.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $104.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.93 | 2019-2020 | |
| Sanofi Pasteur INC. | $63.73 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $56.03 | 2019-2020 | |
| Abbott Laboratories | $47.48 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.73 | 2019 | |
| Genentech USA, INC. | $22.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.